Coverage
-
April 06, 2020
Mylan has successfully persuaded the Patent Trial and Appeal Board that one claim of a Sanofi-Aventis patent covering the Lantus SoloStar disposable insulin injection pen is invalid as obvious.
1 other articles on this case.
View all »